Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Gastroprotective Agent Compliance in Patients at Risk Suffering From a Gastrointestinal(GI) Ulcer

This study has been withdrawn prior to enrollment.
Information provided by:
AstraZeneca Identifier:
First received: September 28, 2010
Last updated: October 21, 2010
Last verified: October 2010
The purpose of this study is to assess gastroprotective agent compliance in patients at risk suffering from a gastrointestinal bleeding ulcer or a symptomatic ulcer with NSAID.

Gastrointestinal Hemorrhage

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Gastroprotective Agent Compliance in Patients at Risk Suffering From a Gastrointestinal Bleeding Ulcer or a Symptomatic Ulcer With Non-steroidal Anti-inflammatory Drug (NSAID) in France

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Gastroprotective agent compliance [ Time Frame: At the end of 1 month ]

Secondary Outcome Measures:
  • Clinical characteristics of those ulcers with NSAID [ Time Frame: At the end of 1 month ]

Enrollment: 0
Study Start Date: October 2010
Estimated Study Completion Date: April 2011
Estimated Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Hospital sample

Inclusion Criteria:

  • Patients at risk suffering from a gastrointestinal bleeding ulcer or a symptomatic ulcer confirmed by endoscopy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01215058

Sponsors and Collaborators
Study Chair: Jean-Francois Bretagne Service gastro-enterologie et hepatologieCHRU Pontchaillou35033 RENNES cedex France
Study Chair: Gerard Thiefin Service Hepato-Gastroenterologie CHU Reims51092 REIMS cedex France
Principal Investigator: Genevieve BONNELYE KantarHealth - France138, avenue Marx Dormoy92120 Montrouge cedex
  More Information

Responsible Party: Marketing Company Medical Director, AstraZeneca Identifier: NCT01215058     History of Changes
Other Study ID Numbers: NIS-PFR-DUM-2010/2
Study First Received: September 28, 2010
Last Updated: October 21, 2010

Keywords provided by AstraZeneca:
Compliance, France
Gastrointestinal bleeding ulcer or symptomatic ulcer with NSAID

Additional relevant MeSH terms:
Gastrointestinal Hemorrhage
Pathologic Processes
Gastrointestinal Diseases
Digestive System Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on April 28, 2017